Brief: Homology Medicines Announces Plan To Evaluate Strategic Options For The Company And Its Genetic Medicines Programs

Q32 Bio

27/07/2023 23:17

July 27 (Reuters) - Homology Medicines Inc  FIXX.O :
    * HOMOLOGY MEDICINES ANNOUNCES PLAN TO EVALUATE STRATEGIC
OPTIONS
FOR THE COMPANY AND ITS GENETIC MEDICINES PROGRAMS, INCLUDING
HMI-103 GENE EDITING CANDIDATE FOR PKU
    * HOMOLOGY MEDICINES INC - ANNOUNCED TODAY ENCOURAGING
INITIAL
CLINICAL DATA FROM FIRST DOSE LEVEL OF PHEEDIT TRIAL EVALUATING
HMI-103
    * HOMOLOGY MEDICINES INC - BOARD OF DIRECTORS HAS APPROVED A
PLAN
TO EVALUATE STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE
    * HOMOLOGY MEDICINES INC - HOMOLOGY HAS RETAINED TD COWEN AS
ITS
STRATEGIC FINANCIAL ADVISOR
    * HOMOLOGY MEDICINES INC - REDUCING ITS WORKFORCE BY 87%
    * HOMOLOGY MEDICINES INC - STOPPING FURTHER PROGRAM
DEVELOPMENT
EFFORTS OUTSIDE OF REQUIRED ACTIONS
    * HOMOLOGY MEDICINES INC - THE MEASURES ARE EXPECTED TO
EXTEND
HOMOLOGY'S CASH RUNWAY INTO 2026
    * HOMOLOGY MEDICINES - STRATEGIC OPTIONS MAY INCLUDE BUT ARE
NOT
LIMITED TO, ACQUISITION, MERGER, REVERSE MERGER, SALE OF ASSETS,
STRATEGIC PARTNERSHIPS
    * HOMOLOGY MEDICINES INC - AS OF MARCH 31, 2023, HOMOLOGY
HAD
APPROXIMATELY $150.0 MILLION IN CASH, CASH EQUIVALENTS AND
SHORT-TERM INVESTMENTS

Source text for Eikon:  ID:nGNXss3qj 
Further company coverage:  FIXX.O 

 (Reuters.Briefs@thomsonreuters.com)